Literature DB >> 12093889

Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II.

Zhonghua Qi1, Chuan-Ming Hao, Robert I Langenbach, Richard M Breyer, Reyadh Redha, Jason D Morrow, Matthew D Breyer.   

Abstract

Therapeutic use of cyclooxygenase-inhibiting (COX-inhibiting) nonsteroidal antiinflammatory drugs (NSAIDs) is often complicated by renal side effects including hypertension and edema. The present studies were undertaken to elucidate the roles of COX1 and COX2 in regulating blood pressure and renal function. COX2 inhibitors or gene knockout dramatically augment the pressor effect of angiotensin II (Ang II). Unexpectedly, after a brief increase, the pressor effect of Ang II was abolished by COX1 deficiency (either inhibitor or knockout). Ang II infusion also reduced medullary blood flow in COX2-deficient but not in control or COX1-deficient animals, suggesting synthesis of COX2-dependent vasodilators in the renal medulla. Consistent with this, Ang II failed to stimulate renal medullary prostaglandin E(2) and prostaglandin I(2) production in COX2-deficient animals. Ang II infusion normally promotes natriuresis and diuresis, but COX2 deficiency blocked this effect. Thus, COX1 and COX2 exert opposite effects on systemic blood pressure and renal function. COX2 inhibitors reduce renal medullary blood flow, decrease urine flow, and enhance the pressor effect of Ang II. In contrast, the pressor effect of Ang II is blunted by COX1 inhibition. These results suggest that, rather than having similar cardiovascular effects, the activities of COX1 and COX2 are functionally antagonistic.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12093889      PMCID: PMC151026          DOI: 10.1172/JCI14752

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  65 in total

1.  Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids.

Authors:  F Catella-Lawson; B McAdam; B W Morrison; S Kapoor; D Kujubu; L Antes; K C Lasseter; H Quan; B J Gertz; G A FitzGerald
Journal:  J Pharmacol Exp Ther       Date:  1999-05       Impact factor: 4.030

Review 2.  Regulated formation of eicosanoids.

Authors:  F A Fitzpatrick; R Soberman
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

3.  Salt-sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor.

Authors:  C R Kennedy; Y Zhang; S Brandon; Y Guan; K Coffee; C D Funk; M A Magnuson; J A Oates; M D Breyer; R M Breyer
Journal:  Nat Med       Date:  1999-02       Impact factor: 53.440

4.  Cyclooxygenase-2--specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients.

Authors:  A Whelton; J G Fort; J A Puma; D Normandin; A E Bello; K M Verburg
Journal:  Am J Ther       Date:  2001 Mar-Apr       Impact factor: 2.688

5.  Arachidonic acid is preferentially metabolized by cyclooxygenase-2 to prostacyclin and prostaglandin E2.

Authors:  T G Brock; R W McNish; M Peters-Golden
Journal:  J Biol Chem       Date:  1999-04-23       Impact factor: 5.157

6.  Role of renocortical cyclooxygenase-2 for renal vascular resistance and macula densa control of renin secretion.

Authors:  Hayo Castrop; Frank Schweda; Karl Schumacher; Konrad Wolf; Armin Kurtz
Journal:  J Am Soc Nephrol       Date:  2001-05       Impact factor: 10.121

7.  Cyclooxygenase 2 and neuronal nitric oxide synthase expression in the renal cortex are not interdependent in states of salt deficiency.

Authors:  H Castrop; M Kammerl; B Mann; B L Jensen; B K Krämer; A Kurtz
Journal:  Pflugers Arch       Date:  2000-12       Impact factor: 3.657

8.  Genetic deletion of COX-2 prevents increased renin expression in response to ACE inhibition.

Authors:  H F Cheng; J L Wang; M Z Zhang; S W Wang; J A McKanna; R C Harris
Journal:  Am J Physiol Renal Physiol       Date:  2001-03

9.  Increased renal vasodilator prostanoids prevent hypertension in mice lacking the angiotensin subtype-2 receptor.

Authors:  H M Siragy; T Senbonmatsu; T Ichiki; T Inagami; R M Carey
Journal:  J Clin Invest       Date:  1999-07       Impact factor: 14.808

10.  Selective targeting of cyclooxygenase-2 reveals its role in renal medullary interstitial cell survival.

Authors:  C M Hao; M Kömhoff; Y Guan; R Redha; M D Breyer
Journal:  Am J Physiol       Date:  1999-09
View more
  72 in total

Review 1.  The choreography of cyclooxygenases in the kidney.

Authors:  G A FitzGerald
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

2.  An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension.

Authors:  John D Imig; Xueying Zhao; Constantine Z Zaharis; Jeffrey J Olearczyk; David M Pollock; John W Newman; In-Hae Kim; Takaho Watanabe; Bruce D Hammock
Journal:  Hypertension       Date:  2005-09-12       Impact factor: 10.190

Review 3.  Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities.

Authors:  Tilo Grosser; Susanne Fries; Garret A FitzGerald
Journal:  J Clin Invest       Date:  2006-01       Impact factor: 14.808

4.  Resistance to hypertension mediated by intercalated cells of the collecting duct.

Authors:  Johannes Stegbauer; Daian Chen; Marcela Herrera; Matthew A Sparks; Ting Yang; Eva Königshausen; Susan B Gurley; Thomas M Coffman
Journal:  JCI Insight       Date:  2017-04-06

5.  Enhanced pressor response to acute Ang II infusion in mice lacking membrane-associated prostaglandin E2 synthase-1.

Authors:  Dong-juan Zhang; Li-hong Chen; Ya-hua Zhang; Guang-rui Yang; Dou Dou; Yuan-sheng Gao; Xiao-yan Zhang; Xiao-mu Kong; Pan Zhao; Dan Pu; Ming-fen Wei; Matthew-D Breyer; You-fei Guan
Journal:  Acta Pharmacol Sin       Date:  2010-09-27       Impact factor: 6.150

6.  Activation of prostaglandin E2 EP1 receptor increases arteriolar tone and blood pressure in mice with type 2 diabetes.

Authors:  Ibolya Rutkai; Attila Feher; Nora Erdei; Daniel Henrion; Zoltan Papp; Istvan Edes; Akos Koller; Gabor Kaley; Zsolt Bagi
Journal:  Cardiovasc Res       Date:  2009-03-19       Impact factor: 10.787

7.  Antihypertensive effects of selective prostaglandin E2 receptor subtype 1 targeting.

Authors:  Youfei Guan; Yahua Zhang; Jing Wu; Zhonghua Qi; Guangrui Yang; Dou Dou; Yuansheng Gao; Lihong Chen; Xiaoyan Zhang; Linda S Davis; Mingfeng Wei; Xuefeng Fan; Monica Carmosino; Chuanming Hao; John D Imig; Richard M Breyer; Matthew D Breyer
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

8.  Coingestion of cyclooxygenase inhibitors can worsen severe paracetamol poisoning by middle-sized and small arteries vasoconstriction.

Authors:  Francis Schneider; Agnès Neuville; Ferhat Meziani; Carole Meyer; Parissa Assemi; Thierry Lavigne; Vincent Castelain
Journal:  Intensive Care Med       Date:  2003-09-26       Impact factor: 17.440

9.  Renal Medullary Interstitial COX-2 (Cyclooxygenase-2) Is Essential in Preventing Salt-Sensitive Hypertension and Maintaining Renal Inner Medulla/Papilla Structural Integrity.

Authors:  Ming-Zhi Zhang; Suwan Wang; Yinqiu Wang; Yahua Zhang; Chuan Ming Hao; Raymond C Harris
Journal:  Hypertension       Date:  2018-11       Impact factor: 10.190

10.  Effect of selective cyclooxygenase-2 (COX-2) inhibitor treatment on glucose-stimulated insulin secretion in C57BL/6 mice.

Authors:  Hiroki Fujita; Masafumi Kakei; Hiromi Fujishima; Tsukasa Morii; Yuichiro Yamada; Zhonghua Qi; Matthew D Breyer
Journal:  Biochem Biophys Res Commun       Date:  2007-08-27       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.